Amy Ripka, CEO of Lucy Therapeutics, was recently interviewed for American Chemical Society’s Industry Matters Newsletter

Feb 15, 2021

ACS – “Amy Ripka is CEO of Lucy Therapeutics, a Boston-based, mitochondrial platform biotech, revolutionizing treatments for rare and neurological diseases. Previous to her role at LucyTx, she served on the executive leadership teams at SAI Life Sciences and WuXiAppTec. Dr. Ripka previously held positions of scientific leadership at EnVivo Pharmaceuticals, Daiamed and Infinity Pharmaceuticals as well as consulting for other Boston biotechs such as FoldRx (acquired by Pfizer) and Hydra Biosciences. She received her PhD in Organic Chemistry from the University of Wisconsin-Madison and subsequently worked in the lab of Nobel Laureate K. Barry Sharpless for her post-doctoral studies. She has over 30 issued patents and has been involved in multiple INDs in different therapeutic areas. She has deep connections in the medicinal chemistry community with long-time service to the ACS MEDI Executive Committee and was the elected Chair of the 2012 Medicinal Chemistry Gordon Research Conference. She is currently a SAB member at Carraway Therapeutics and Q BioMed. In her spare time, she plays classical violin professionally in and around the Boston area and has performed with such artists as Yo-Yo Ma, Hillary Hahn, Peter Gabriel, Sarah McLachlan and Smokey Robinson.” 


About Lucy Therapeutics

Lucy Therapeutics develops chemical therapeutics to treat mitochondrial dysfunction. Mitochondrial dysfunction, caused by disease, may contribute to the complex pathology seen in certain diseases like Rett Syndrome, Parkinson’s, Alzheimer’s and COVID-19.

The latest from our portfolio companies that are changing the world.

Safar Partners is committed to funding technological advances that create value.


Interested in partnering with us?

Contact Information

Safar Partners
One Broadway, 14th floor, 
Cambridge, MA 02142